Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- p53 is a tumor suppressor
- Evidence that p53 is a tumor suppressor
- Additional evidence that p53 is a tumor suppressor
- Half of all human cancers carry p53 mutations
- p53 is a sequence-specific transcription factor
- Schematic structure of p53 protein
- Example: the biological activities of p53
- Effect of temperature-sensitive p53 activation
- Induction of cell death by activated p53
- Activated p53 induces apoptosis in leukemic cells
- p53 is activated by oncogenic stress
- p53 is activated by various cellular stress types
- Induction of p53 by DNA damage (cisplatin)
- How is p53 activated?
- Some p53 target genes
- Activity of transcriptional activation-deficient p53
- Translocation of p53 in response to DNA damage
- Transcription activity in response to DNA damage
- Mitochondrially targeted p53
- Mitochondrially targeted p53 induces apoptosis
- Transcriptional activation-deficient and wt p53
- PUMA releases p53 from Bcl-xL
- Integrated apoptotic activities of p53
- How is p53 activity restrained in absence of stress
- MDM2 - a negative regulator of p53
- Basic facts about MDM2
- How does MDM2 inactivate p53?
- MDM2 promotes degradation of p53
- p53 levels determine its fate
- p53-MDM2 negative autoregulatory feedback loop
- Disrupting the p53-MDM2 feedback loop
- p53 in evolution
- p53 transcriptional activity in drosophila embryo
- Effect of dominant negative p53 activity in the fly
- C.elegans p53 is required for germ cell apoptosis
- How is the outcome of p53 activation determined
- p53 activation: growth arrest or cell death?
- Induction of p21 by p53 can inhibit apoptosis
- Some p53 target genes are anti-apoptotic
- p53 mutations lead to different effects on its action
- Mutant p53 overexpression prevents apoptosis
- Mutant p53 protects cancer cells from killing
- Knock-down of mutant p53 restores killing
- Mutant p53 down-regulates surface CD95 protein
- Mutant p53 down-regulates the CD95 promoter
- p53-based cancer therapy
- p53-MDM2 binding
- Drugs that disrupt p53-mdm2 binding - Nutlin
- Nutlin induces p53 activation/ tumor regression
- PRIMA-1 affects mutant p53
- PRIMA-1 synergizes with cisplatin
- Summary
Topics Covered
- p53 as a tumor suppressor
- Regulation of transcription by p53
- Activation of p53 by oncogenic stress
- Transcriptional and non-transcriptional mechanisms for p53- mediated apoptosis
- Regulation of p53 by Mdm2
- Evolutionary conservation of p53 function
- Mutant p53 gain of function
- p53-based cancer therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Oren, M. (2007, October 1). p53 and apoptosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/AYTF7064.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Moshe Oren has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.